Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
- Conditions
- HIV Infections
- Registration Number
- NCT00028301
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.
- Detailed Description
The study is designed to determine the metabolic changes, antiviral activity, safety, and tolerability of atazanavir as compared to LPV/RTV, each in combination with 2 nucleosides, over the initial 24 weeks, with a final analysis at 48 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (97)
Cooper Green Hosp
🇺🇸Birmingham, Alabama, United States
Phoenix Body Positive
🇺🇸Phoenix, Arizona, United States
East Bay AIDS Ctr
🇺🇸Berkeley, California, United States
Saint Francis Mem Hosp / HIV Care Unit
🇺🇸San Francisco, California, United States
Kaiser Foundation Hospital
🇺🇸San Francisco, California, United States
San Francisco Veterans Administration Med Ctr
🇺🇸San Francisco, California, United States
Harbor UCLA Med Ctr
🇺🇸Torrance, California, United States
Beacon Clinic / Boulder Community Hosp
🇺🇸Boulder, Colorado, United States
IDC Research Initiative
🇺🇸Altamonte Springs, Florida, United States
Larry Bush
🇺🇸Atlantis, Florida, United States
Scroll for more (87 remaining)Cooper Green Hosp🇺🇸Birmingham, Alabama, United States